Regarding trastuzumab therapy, activating mutations in the PIK3CA gene have been described to be associated with a poorer therapy outcome in breast cancer patients (Berns et al. 2007; Majewski et al. 2015). The gene discussed is PIK3CA; the disease is breast carcinoma.